Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone

With more and more PD-(L)1 checkpoint inhibitors flooding the market, there has been a long-running war over which of those drugs can secure a lead in early-line patients. With Keytruda on top of the world, Merck is well-positioned to take the lead — and it’s rolling out a pair of studies targeted directly at that front.